Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227602 · ClinicalTrials.gov registry record · NA
Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease
A NA study of Ulcerative Colitis and Crohn Disease, sponsored by Texas A&M University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02227602: Completed NA study of Ulcerative Colitis and Crohn Disease, sponsored by Texas A&M University.
NCT02227602 is a NA study of Ulcerative Colitis and Crohn Disease that has completed, run by Texas A&M University. The registered enrollment target is 20 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02227602, a NA study of Ulcerative Colitis and Crohn Disease, has completed, sponsored by Texas A&M University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Bioactive compounds from mango are bioavailable and their anti-inflammatory efficacy has been demonstrated in animals and humans. However, the efficacy of mangoes has not previously been compared with respect to mild inflammatory bowel disease. In order to justify future pharmacokinetic and pharmacodynamic analyses in human clinical trials, a pilot assessment to determine efficacy in preventing or resolving Inflammatory bowel disease is a necessary step. Therefore, in this aim we will determine the clinical relevance of mango as an adjuvant treatment to conventional therapy in Inflammatory bowel disease . The effects of mango with common drug treatment in mild-moderate Inflammatory bowel disease will be compared to the drug-treatment alone. If mango or any other polyphenolic-rich food could be identified as helpful in shortening or reducing severity of episodes of inflammatory bowel disease, the addition of polyphenolics to conventional drug treatment in Inflammatory bowel disease would have a significant impact on public health.
Primary Outcome
* A questionnaire used to assess the severity of symptoms in people who suffer from ulcerative colitis * The score ranges from 0 to 19, where active disease is a score of 5 or higher * compare changes in the score during the study
Conditions Studied
Interventions
- DRUG Mango polyphenolics
Study Locations (1)
Texas
- Texas A&M University, Clinical Lab, Nutrition and Food Science Department - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-03 |
| Phase | NA |
What the finished NCT02227602 record still lists
NCT02227602 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Mango polyphenolics is the first listed.
NCT02227602 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02227602 about?
NCT02227602 is a clinical study titled "Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease". Bioactive compounds from mango are bioavailable and their anti-inflammatory efficacy has been demonstrated in animals and humans. However, the efficacy of mangoes has not previously been compared with respect to mild inflammatory bowel disease. In order to justify future pharmacokinetic and pharmaco...
What is the current status of trial NCT02227602?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2014-01. Estimated completion is 2018-03.
What conditions does trial NCT02227602 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn Disease, Intestinal Diseases.
What interventions are being tested in trial NCT02227602?
The interventions under investigation include: Mango polyphenolics (DRUG).
Who is sponsoring clinical trial NCT02227602?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02227602 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02227602's enrollment target sits among peer trials
20 112th of 122 higher than 8 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
-
Fermented Food-Supplemented Diet in Ulcerative Colitis
RECRUITING · NA
-
Impact of Prebiotics in Ulcerative Colitis
RECRUITING · NA
-
Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia